Co-Diagnostics Announces Publication Of Peer-Reviewed Study Using SARAGENE Human Papillomavirus High Risk Test Manufactured By CoSara Diagnostics
Benzinga Newsdesk 2 days ago
News
Follow-Up Biopsies Identified High-Grade Lesions or Cervical Cancer in 12 of 20 HPV-Positive Women, Including a Cohort with Predominantly Negative Cytology ResultsCoSara to Exhibit at MICROCON 2026, the Annual Congress
Follow-Up Biopsies Identified High-Grade Lesions or Cervical Cancer in 12 of 20 HPV-Positive Women, Including a Cohort with Predominantly Negative Cytology Results
CoSara to Exhibit at MICROCON 2026, the Annual Congress of the Indian Association of Medical Microbiologists
Co-Dx to Host HPV Screening Webinar on November 17 to Support Awareness Across South Asian Markets
SALT LAKE CITY, Oct. 29, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the publication of a peer-reviewed study using the SARAGENE® Human Papillomavirus High Risk (HPV-HR) Test manufactured by CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India. The study, conducted by investigators at a local institution in Gujarat, India and published in Infectious Agents and Cancer, highlights the potential role of molecular HPV testing in identifying women who warrant further evaluation, even when cytology results are negative.